Table 2.

Summary of antiviral therapy, HBV polymerase and concomitant surface gene sequence data in liver, PBMC and plasma of patients on suppressive anti-HBV therapy

Case	Current antiviral (prior therapy) duration (months)*	Anti-HBV drug resistance (clinical)	Plasma† % wt or drug-resistant and S gene alterations	Liver† % wt or drug-resistant and S gene alterations	PBMC† % wt or drug-resistant and S gene alterations
1	ETV 9	LMV	–	wt, 100%	–
2	LMV, ADF 30	LMV	–	LMV, 40% (rtM204I; sW743L) wt, 60%	–
3	LMV, TDF (ADV) 7	LMV, ADF	–	LMV, 20% (rtM204V; sI741M) ADF 10% (rtA181V; sF674L)	–
4	TDF (ADV) 19	No	–	ADF, 20% (rtA181S; sW673C) wt 80%	wt, 100%
5	LMV 38	No	–	wt, 100%	wt, 100%
6	FTC, TDF (LMV, ADV) 6	Slow response to ADF	wt, 100%	LMV, 30% (rtM204I; sW743stop) wt, 70%	LMV, 16% (rtM204I; sI741M) ETV, 11% (rtS184N; sV685M) wt, 73%
7	LMV 15	No	wt, 100%	wt, 100%	wt, 100%
8	ADV (LMV) 8	LMV	–	‡LMV, 50% (rtM204V or rtL180M; sI741M) wt, 50%	–
9	LMV, TDF 36	No	–	LMV, 5% (rtL180P; sS667P) wt, 95%	wt, 100%

PBMC, peripheral blood mononuclear cells; ETV, entecavir; LMV; lamivudine; ADF, adefovir; TDF; tenofovir; FTC, emtricitabine; wt, wild-type; ADV, adefovir.

^*Median duration of antiviral therapy 15 months, range 6–38 months.

^†10–20 clones of HBV P gene sequence analysed in liver and 20 clones analysed in PBMC and plasma.

^‡Case 8 Liver: 50% clones carried wt HBV P gene and 50% LMVr variants rtM204V or rtL180M.